1. Efficacy signals, long-term exposure and safety data from a phase 1–2 study of a cell-penetrating peptide antagonist of CEBPβ, a novel target, in patients (pts) with refractory solid tumors. (October 2022) Authors: Fontana, E.; Williams, A.; Falchook, G.; Lakhani, N.; Evans, T.R.J.; Gondi, V.; Iwamoto, F.; McKean, M.; Symeonides, S.; Butowski, N.; McLaren, A.; Henry, J.; Buerki, R.; Rotolo, J.; Capiaux, G.; Michel, R.; Kaesshaefer, S.; Wiegert, E.; Bexon, A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. MDNA55, a Locally Administered IL4 Guided Toxin for Targeted Treatment of Recurrent Glioblastoma Shows Long Term Survival Benefit. (October 2020) Authors: Sampson, J.; Achrol, A.S.; Aghi, M.K.; Bankiewicz, K.; Bexon, M.; Brem, S.; Brenner, A.; Chowdhary, S.; Coello, M.; Ellingson, B.M.; Floyd, J.R.; Han, S.; Kesari, S.; Merchant, F.; Merchant, N.; Randazzo, D.; Vogelbaum, M.; Vrionis, F.; Zabek, M.; Butowski, N. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PC3 - 154 Phase I/II Study of VAL-083 in Patients with Recurrent Glioblastoma. (18th October 2016) Authors: Shih, K.C.; Patel, M.R.; Butowski, N.; Falchook, G.S.; Kizilbash, S.H.; Bacha, J.A.; Brown, D.M.; Steino, A.; Schwartz, R.; Kanekal, S.; Lopez, L.M.; Burris, H.A. Journal: Canadian journal of neurological sciences Issue: Volume 43(2016)Supplement 4 Page Start: S18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗